دورية أكاديمية
Plasma exchange in thrombotic thrombocytopenic purpuras.
| عنوان ترانسليتريتد: | Plasma exchange in thrombotic thrombocytopenic purpuras. |
|---|---|
| المؤلفون: | Jabr D; Clinical Hematology Department, Aziza Othmana Hospital, Faculty of Medicine of Tunis, University of Tunis el Manar, Tunis, Tunisia., Hsasna R; Clinical Hematology Department, Aziza Othmana Hospital, Faculty of Medicine of Tunis, University of Tunis el Manar, Tunis, Tunisia., Kefi S; Clinical Hematology Department, Aziza Othmana Hospital, Faculty of Medicine of Tunis, University of Tunis el Manar, Tunis, Tunisia., Kharrat R; Clinical Hematology Department, Aziza Othmana Hospital, Faculty of Medicine of Tunis, University of Tunis el Manar, Tunis, Tunisia., Ben Neji H; Clinical Hematology Department, Aziza Othmana Hospital, Faculty of Medicine of Tunis, University of Tunis el Manar, Tunis, Tunisia., Ben Lakhal R; Clinical Hematology Department, Aziza Othmana Hospital, Faculty of Medicine of Tunis, University of Tunis el Manar, Tunis, Tunisia. |
| المصدر: | La Tunisie medicale [Tunis Med] 2024 Jun 05; Vol. 102 (6), pp. 343-347. Date of Electronic Publication: 2024 Jun 05. |
| نوع المنشور: | English Abstract; Journal Article |
| اللغة: | French |
| بيانات الدورية: | Publisher: Societe Tunisienne Des Sciences Medicales Country of Publication: Tunisia NLM ID: 0413766 Publication Model: Electronic Cited Medium: Internet ISSN: 2724-7031 (Electronic) Linking ISSN: 00414131 NLM ISO Abbreviation: Tunis Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Tunis : Societe Tunisienne Des Sciences Medicales |
| مواضيع طبية MeSH: | Purpura, Thrombotic Thrombocytopenic*/therapy , Purpura, Thrombotic Thrombocytopenic*/diagnosis , Plasma Exchange*/methods, Humans ; Retrospective Studies ; Female ; Male ; Middle Aged ; Adult ; Young Adult ; Treatment Outcome ; Aged ; Recurrence ; Plasmapheresis/methods ; Adolescent ; Rituximab/therapeutic use ; Rituximab/administration & dosage |
| مستخلص: | Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially fatal hematological disorder that requires urgent treatment. Once the diagnosis has been made, plasma exchange (PE) must be started immediately and until a response is obtained. Aim: Evaluate PE in terms of responses and complications in the treatment of TTP. Methods: This was a monocentric, descriptive, retrospective study including patients in whom TTP was diagnosed and treated with plasmapheresis in the clinical hematology department at Aziza Othmana Hospital, between January 2010 and December 2020. Results: Our study included 26 patients. PE was initiated within a median of 1 day. The rhythm of exchanges was daily in 22 patients. Twenty PE-related complications were noted, hypocalcemia being the most frequent (30%). CR was achieved in 15 patients after PE alone. Nine patients were refractory, and six received 2nd-line treatment, with CR achieved in five patients. Relapse was noted in six patients (40%). They were treated by PE and only one patient received rituximab. Four patients had a response. The overall response rate was 69% and overall mortality was 30%. OS at 2 years was 68,3% and RFS was 84,4%. Factors associated with the achievement of CR were the fall in LDH at D5 of treatment (p=0,027,OR=0,59 ;IC 95%[0,32-1,08]) and the daily rhythm of PE (p=0,005, OR=0,35; IC 95%[0,14-0,91]). Conclusion: Our results were comparable to those of the literature, but the rate of refractory disease was higher. Rituximab may enhance our results. |
| References: | Semin Thromb Hemost. 2005 Dec;31(6):700-8. (PMID: 16388421) Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):632-638. (PMID: 29222314) Eur J Haematol. 2009 Oct;83(4):365-72. (PMID: 19508684) Rev Med Interne. 2016 Jan;37(1):13-8. (PMID: 26065327) J Clin Apher. 2007;22(5):270-6. (PMID: 17722046) J Clin Apher. 2014 Jun;29(3):148-67. (PMID: 24136342) Blood. 2010 Nov 18;116(20):4060-9. (PMID: 20686117) Am J Hematol. 1987 Apr;24(4):329-39. (PMID: 3565371) N Engl J Med. 1998 Nov 26;339(22):1578-84. (PMID: 9828245) Lancet Haematol. 2016 May;3(5):e237-45. (PMID: 27132698) Br J Haematol. 2008 Sep;142(5):819-26. (PMID: 18637802) Intensive Care Med. 2022 Oct;48(10):1382-1396. (PMID: 35960275) Arch Intern Med. 1992 Apr;152(4):791-6. (PMID: 1558437) Am J Med. 1999 Dec;107(6):573-9. (PMID: 10625026) Ann Intern Med. 1995 Apr 15;122(8):569-72. (PMID: 7887549) Br J Haematol. 2006 Jan;132(2):204-9. (PMID: 16398654) Blood. 2010 Feb 25;115(8):1500-11; quiz 1662. (PMID: 20032506) J Emerg Med. 2012 Sep;43(3):538-44. (PMID: 22445678) Br J Haematol. 2007 Feb;136(3):451-61. (PMID: 17233847) J Clin Apher. 1998;13(3):133-41. (PMID: 9828024) Br J Haematol. 2012 Aug;158(3):323-35. (PMID: 22624596) Presse Med. 1991 Nov 9;20(36):1761-7. (PMID: 1836595) Hematol Oncol Clin North Am. 2016 Jun;30(3):679-94. (PMID: 27113004) PLoS One. 2010 Apr 23;5(4):e10208. (PMID: 20436664) J Thromb Haemost. 2010 Jun;8(6):1201-8. (PMID: 20175870) N Engl J Med. 1991 Aug 8;325(6):393-7. (PMID: 2062330) Am J Hematol. 1994 Oct;47(2):94-9. (PMID: 8092147) J Clin Apher. 2019 Jun;34(3):171-354. (PMID: 31180581) |
| فهرسة مساهمة: | Keywords: Plasmapheresis; Survival; Thrombotic microangiopathies; Thrombotic thrombocytopenic purpura |
| المشرفين على المادة: | 4F4X42SYQ6 (Rituximab) |
| تواريخ الأحداث: | Date Created: 20240612 Date Completed: 20240612 Latest Revision: 20240914 |
| رمز التحديث: | 20240914 |
| مُعرف محوري في PubMed: | PMC11358829 |
| DOI: | 10.62438/tunismed.v102i6.4614 |
| PMID: | 38864197 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2724-7031 |
|---|---|
| DOI: | 10.62438/tunismed.v102i6.4614 |